Skip to main content

  • UK’s NICE approves aflibercept for BRVO

    PMLiVE
    Retina/Vitreous
    Add to My Bookmarks

    The National Institute for Health Care Excellence (NICE) has recommended aflibercept as a first-line treatment of branched retinal vein occlusion (BRVO) for adult patients in England and Wales.

    The decision is based on recent clinical data suggesting that aflibercept leads to better visual outcomes and has higher efficacy when used prior to laser treatment, making it the more cost-effective option.

    NICE has previously approved aflibercept for wet AMD, central retinal vein occlusion, DME and myopic choroidal neovascularization.

    The NHS has 90 days to make the treatment accessible to more than 13,000 patients in England and Wales with BRVO.

    “I am pleased that NICE has finalized this guidance for aflibercept as I am now able to offer an anti-VEGF as a first-line treatment option to patients with BRVO,” said Dr. Sobha Sivaprasad, consultant ophthalmologist at Moorfields Eye Hospital. “This will allow patients to achieve the best possible clinical outcomes upon diagnosis and the opportunity to achieve the positive visual outcomes that we see in real-life clinical practice across other retinal conditions.”